Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide

Exclusion Criteria

• •Any history of a primary or secondary headache disorder other than migraine without aura, migraine with aura, chronic migraine, and episodic tension-type headache
• •History or evidence of any other clinically significant disorder, condition, or disease (except for those outlined above) that, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion
• •The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior
• •Female subjects of childbearing potential with a positive pregnancy test during any study visit
• •Cardiovascular disease of any kind, including cerebrovascular diseases
• •Hypertension (systolic blood pressure of ≥150 mmHg and/or diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day
• •Hypotension (systolic blood pressure of ≤90 mmHg and/or diastolic blood pressure of ≤50 mmHg)
• •Initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion
• •Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start
• •Headache of any intensity within 48 hours of infusion start
• •Aura within 48 hours of infusion start